|
1. Indications And Usage Symtuza Is Indicated As A Complete Regimen For The Treatment Of Human Immunodeficiency Virus Type 1 (Hiv-1) Infection In Adults And Pediatric Patients Weighing At Least 40 Kg: Who Have No Prior Antiretroviral Treatment History Or Who Are Virologically Suppressed (Hiv-1 Rna Less Than 50 Copies Per Ml) On A Stable Antiretroviral Regimen For At Least 6 Months And Have No Known Substitutions Associated With Resistance To Darunavir Or Tenofovir. Symtuza Is A Four-Drug Combination Of Darunavir (Drv), A Human Immunodeficiency Virus (Hiv-1) Protease Inhibitor, Cobicistat (Cobi), A Cyp3a Inhibitor, And Emtricitabine (Ftc) And Tenofovir Alafenamide (Taf), Both Hiv-1 Nucleoside Analog Reverse Transcriptase Inhibitors, And Is Indicated As A Complete Regimen For The Treatment Of Hiv-1 Infection In Adults And Pediatric Patients Weighing At Least 40 Kg: Who Have No Prior Antiretroviral Treatment History Or Who Are Virologically Suppressed (Hiv-1 Rna Less Than 50 Copies Per Ml) On A Stable Antiretroviral Regimen For At Least 6 Months And Have No Known Substitutions Associated With Resistance To Darunavir Or Tenofovir. ( 1 )
|